New research to be presented at the European Congress on Obesity (ECO 2025, Malaga, Spain, 11–14 May) shows that around ...

A new study reveals that taking tirzepatide once a week can lead to significant and long-lasting weight loss for up to three ...

Physicians are turning to other options, including older, cheaper medications, as compounding GLP-1s comes to an end.

You may know about tirzepatide, also known as Mounjaro or Zepbound, due to its popularity for those looking to lose weight or treat diabetes. Now, researchers have gotten it approved to treat sleep ...

A recent Italian study reveals Mounjaro's effectiveness in maintaining weight loss over three years, particularly benefiting ...

New research to be presented at the European Congress on Obesity (ECO 2025, Malaga, Spain, 11–14 May) shows that patients ...

New research to be presented at this year's European Congress on Obesity (ECO 2025, Malaga, Spain, 11-14 May) shows that around two thirds of participants of the SURMOUNT-1 trial had only regained 5% ...

Eli Lilly just pre-announced a $1.57 billion pre-tax charge related to acquired in-process R&D, which is expected to weigh ...

Patients with type 2 diabetes who switched to tirzepatide rather than escalating their dulaglutide dosage had greater weight ...

Karen Coe, 59, who has type 2 diabetes, says she was prescribed a GLP-1 medication to help her lose weight and get her ...

Tirzepatide offers a promising treatment for patients with obesity, chronic kidney disease, and heart failure, improving both ...

As obesity rates rise among individuals with T1D, GLP-1 agonist medications, indicated for T2D and weight loss, are ...